Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Last Year's Top Vaccine Stocks May Win Again in 2021

By Adria Cimino - Updated Jan 28, 2021 at 1:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Share price catalysts are right around the corner.

Novavax (NVAX -0.88%) and Vaxart (VXRT 3.09%) posted increases of more than 2,000% and 1,000% respectively last year. But there may be reasons for these biotech companies to extend their gains in 2021. In this Motley Fool Live video recorded on Jan. 22, 2021, healthcare and cannabis bureau chief Corinne Cardina and contributor Adria Cimino discuss the share potential of both of these companies.

Corinne Cardina: With the pandemic having gone on for a year, and like you mentioned with Novavax, a lot of these stocks have run up so much over the past 12 months. A big point of analysis for investors is valuation. How much of expected success is already baked in, and are there major catalyst in the future that could reward investors who buy at this price? Of course, we talked about Novavax, it was like the second highest flier of 2020, is it too frothy at this price?

Adria Cimino: I think there still is room for share gains, but slower and steady over time. As I mentioned, we're not going to get that 2000% again in one year. But I think over time. Earnings per share estimates for the fiscal year are coming in at the idea of about $21 per share. That's from company that was at losses per share in previous years. I think that with the hopes of the vaccine and the idea of flu vaccine, these can all be something to bet on for longer-term. I also have another one that I want to talk about -- Vaxart -- and that's another big gain last year. They gained more than 1,000%. Vaxart has been working on a tablet form vaccine which is interesting because for people who don't like getting shots, that's pretty good. And also it's room temperature stable, so the idea of cold chain storage and transport, you don't have to worry about. It could be a very interesting product. Now, we're waiting for phase 1 data so it's much earlier stage, so it is riskier bet. Also, it's smaller market cap -- it's $720 million. So, there's definitely room for growth for this stock. It's just that it's going to be a riskier one.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$46.13 (-0.88%) $0.41
Vaxart, Inc. Stock Quote
Vaxart, Inc.
$3.34 (3.09%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.